.png){kind=icon}
.png){kind=icon}
Return
Creatine/Creatinine Ratio and Myostatin as Biomarkers to Monitor Muscle Function in Duchenne Muscular Dystrophy Patients
.png){kind=icon}
OA
AI
C
R
S
N
M
H
E
P
DOI：10.1002/jcsm.70320.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Duchenne Muscular Dystrophy (DMD) is characterized by progressive muscle wasting leading to early loss of motor function. Functional tests monitor disease progression and serve as clinical trial endpoints but are influenced by maturation in younger patients, high intra-patient variability and patient motivation. Clinical milestones, instead, have been used to identify modifiers of disease progression but are rarely used as primary endpoints since clinical trials are usually too short to capture them. Blood biomarkers, that can reflect disease progression and objectively evaluate treatment responses, offer a valuable alternative.
Keywords:
biomarkers
creatine
creatinine
duchenne muscular dystrophy
myostatin
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
9.1
Papers:
2.2K
Citations:
1.4W
Organization
Cited Papers